Details of Torrent Pharmaceuticals and Novo Nordisk’s facility The new plant will allow Novo Nordisk to provide affordable and quality medication to address the growing challenges that this poses.
The new greenfield site will allow Novo Nordisk to meet the increasing demand for insulin products in India.Īccording to the International Diabetes Federation 8th Atlas, India has around 72.9 million diabetes patients, which is expected to increase to around 134.3 million by 2045. The plant has been manufacturing insulin for Novo Nordisk products for more than 15 years. The facility was built as part of an agreement signed by the two companies in August 2005 to dedicate a part of Torrent’s facility to carrying out work related to insulin formulating and packaging. In December 2017, Torrent Pharmaceuticals and Novo Nordisk India opened a greenfield insulin and parenteral facility at Torrent’s parenteral facility in Indrad, Gujarat, India.
